Comparative Pharmacology
Head-to-head clinical analysis: KRINTAFEL versus MALMOREDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KRINTAFEL versus MALMOREDE.
KRINTAFEL vs MALMOREDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KRINTAFEL (tafenoquine) is an 8-aminoquinoline antimalarial that inhibits parasite growth by interfering with the electron transport chain in the mitochondria of Plasmodium species. It is active against both the erythrocytic and exoerythrocytic stages, including hypnozoites of P. vivax.
Malmorede is a synthetic peptide analog of thymosin alpha 1, acting as a biological response modifier. It enhances T-cell maturation and function, increases interleukin-2 production, and modulates immune response by activating dendritic cells and promoting Th1-type cytokine release.
Adults: 200 mg orally as a single dose.
Initial: 50 mg orally twice daily. Maintenance: 100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 5-7 days in healthy subjects. Due to accumulation, steady state is achieved after 4-5 weeks of weekly dosing. In patients with renal impairment, half-life may be prolonged.
4-6 hours; increased in renal impairment (up to 12-15 hours).
Primarily renal; approximately 70-80% of administered dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Fecal excretion accounts for less than 5%.
Primarily renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
Category C
Category C
Antimalarial
Antimalarial